Press Coverage

FDA Clearance for Cellvizio + Pafolacianine for Molecular Imaging

9 May 2022

The US FDA has granted 510(k) clearance (K220477) for the use of the Cellvizio 100 Series platform with a molecular imaging agent called Pafolacianine (Cytalux) for real-time in vivo visualization during endoscopic, laparoscopic, and needle-based procedures, according to Mauna Kea Technologies.

Latest News

Publication of the 2025 Annual Financial Report 

Publication of the 2025 Annual Financial Report 

Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio® To Be Presented at Digestive Disease Week® 2026 

Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio® To Be Presented at Digestive Disease Week® 2026 

Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025 

Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025 

No results found.